Hydroxymethylglutaryl-CoA Reductase Inhibitors
11
0
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
27%
3 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients
Statins in Patients With Type 2 Diabetes Mellitus and Previous History of Acute Coronary Syndrome
The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
Assessment of Change in Atherosclerotic Plaque by Serial CCTA
Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion
Muscle Characteristics Associated With Statin Therapy
Single Dose of Atorvastatin and Circulating Endothelial Microparticles
Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment
The Effect of Statin Medications on Muscle Performance (The STOMP Study)